Janumet 50/500 mg Tablet

Janumet 50/500mg tablet is an antidiabetic medicine used for treating type 2 diabetes mellitus. Type 2 diabetes develops when the body does not produce enough insulin. The medicine contains two active ingredients Sitagliptin (50mg) + Metformin (500mg). Metformin biguanide class belongs to the biguanide class, and Sitagliptin (50mg) belongs to the group class of DPP-4 inhibitors. They together help combine blood sugar levels in people with type 2 diabetic mellitus by improving insulin action and reducing glucose production in the body. The tablet is only indicated for use in adults (18 years and older) and should not be given to children.

• Control blood sugar in a diabetic patient.

Janumet 50/500mg tablet also causes various symptoms, some are mild, and some need proper medical attention to reduce the side effects. Consult the doctor if any of the symptoms persist or worsen:

• Low blood sugar (Hypoglycaemia)
• Lightheadedness
• Dizziness
• Anxiety
• Nervousness
• Tiredness
• Feeling hungry
• Visual disturbances
• Headache
• Shaking
• Sweating
• Pale skin
• Skin rashes
• Pain, redness, swelling at the injection site.

Janumet 50/500mg tablet is a conventional medication used for the management of type 2 diabetes mellitus.  Never self-administer the dose, and if you miss a dose, do not take a double dose to make up for the missed one. It should be taken with a meal to avoid stomach upset. Taking the tablet twice daily at the fixed time every day to enhance the effectiveness of the medication. Always follow the prescription-based medication to avoid complications during the treatment.

The medicine contains two drugs, including Sitagliptin, which increases the level of incretin hormones that help the pancreas release more insulin after meals and reduce the amount of glucose produced by the liver. Metformin works by decreasing glucose production in the liver, reducing absorption of glucose, and improving insulin sensitivity. Together, they provide more effective blood sugar control than either medication used alone. This combination helps maintain stable glucose levels and reduces the risk of diabetes- related complications.

• Bhagyasri, A., Raja, I., Panwar, B., Duggani, M., Nagalla, B., Prabhu, M. U., & Kaktikar, S. Digital Nutrition Counseling and its Impact on Diabetics and Prediabetic Individuals in the Developing Country. https://www.informaticsjournals.co.in/index.php/fijrfn/citationstylelanguage/get/apa?submissionId=44790&publicationId=46187
• Akhtar, J., Khan, M. I., Parveen, S., & Ahmad, A. An update on fixed‐dose combination of SGLT‐2 and DPP‐4 inhibitors in the management of type‐2 diabetes. https://www.researchgate.net/publication/372892117_An_Update_On_Fixed-Dose_Combination_Of_Sglt-2_And_Dpp-4_Inhibitors_In_The_Management_Of_Type-2_Diabetes_Section_A-Research_paper_Eur
• Wavrin, A. M. (2019). Risks and Benefits of Statin Use When at Target Goal. https://www.researchgate.net/publication/372892117_An_Update_On_Fixed-Dose_Combination_Of_Sglt-2_And_Dpp-4_Inhibitors_In_The_Management_Of_Type-2_Diabetes_Section_A-Research_paper_Eur
• Hantash, A. A., Safieh, M. A., Iriqat, S., & Daraghmeh, M. (2021). Bilateral Abducens Nerve Palsy and the possible Association with COVID-19: A Case Report. J. Archives of Medical Case Reports and Case Study, 4(4). https://auctoresonline.org/article/bilateral-abducens-nerve-palsy-and-the-possible-association-with-covid-19-a-case-report
• Gowan, J., & Roller, L. (2016). Disease state management: Diabetes type 2: Improving control by working collaboratively. AJP: The Australian Journal of Pharmacy, 97(1152), 78-86. https://ajp.com.au/cpd/disease-state-management/